Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Receivables (2020 - 2025)

Neuroone Medical Technologies' Receivables history spans 6 years, with the latest figure at $2.7 million for Q4 2025.

  • For Q4 2025, Receivables rose 12.37% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $2.7 million, up 12.37%, while the annual FY2025 figure was $1.3 million, 616.05% up from the prior year.
  • Receivables reached $2.7 million in Q4 2025 per NMTC's latest filing, up from $1.3 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $2.7 million in Q4 2025 to a low of $24628.0 in Q4 2021.
  • Average Receivables over 5 years is $586182.8, with a median of $213952.0 recorded in 2023.
  • Peak YoY movement for Receivables: tumbled 65.54% in 2021, then skyrocketed 616.05% in 2025.
  • A 5-year view of Receivables shows it stood at $24628.0 in 2021, then soared by 287.04% to $95319.0 in 2022, then skyrocketed by 470.08% to $543399.0 in 2023, then surged by 335.94% to $2.4 million in 2024, then grew by 12.37% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Receivables are $2.7 million (Q4 2025), $1.3 million (Q3 2025), and $318780.0 (Q1 2025).